Market Intelligence, Clinical Progress, and High-Purity Reagents for Synucleinopathy and Parkinson's Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for Alpha Synuclein drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Alpha Synuclein Mutant Proteins (A53T, A30P, E46K) Pre-formed Fibrils (PFFs), Monomeric (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View Alpha Synuclein Products |
| Phospho-Variant | pS129 Alpha Synuclein (Phosphorylated) Pathological hallmark mimic, Mass Spec Verified. |
View Alpha Synuclein Products |
| Gene Delivery | SNCA ORF Lentivirus Particles A53T, A30P, WT variants for stable aggregation cell models. |
View Alpha Synuclein Products |
| Benchmark Ab | Anti-Alpha Synuclein (Sequence of Prasinezumab) Recombinant benchmark, C-terminal epitope. |
View Alpha Synuclein Products |
| Validator | SNCA siRNA Set (3 unique sequences) For knockdown verification and specificity controls. |
View Alpha Synuclein Products |
| Related Target A | LRRK2 Genetic modifier pathway, kinase assays for combination therapy. |
View LRRK2 Products |
| Related Target B | PARK7 (DJ-1) Oxidative stress sensor, compensatory pathway analysis. |
View PARK7 Products |
| Related Target C | PINK1 Mitochondrial quality control, mitophagy interaction studies. |
View PINK1 Products |
| Related Target D | GBA Glucocerebrosidase; mutations strongly predispose to SNCA pathology. |
View GBA Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Aggregation Kinetics Standardization | Highly pure monomeric starting material (>95% by SEC-HPLC), endotoxin controlled, ensuring reproducible ThT/fluorescence assays. |
| Pathological Phosphorylation Detection | Ser129 phosphorylated recombinant protein available as validated antigen for pS129 antibody development. |
| Cross-Species Translation (Cyno/Mouse) | Human/Mouse/Rat Alpha Synuclein orthologs with sequence verified identity for preclinical immunogenicity assessment. |
| Oligomer vs Fibril Specificity | Conformation-specific antibody controls and fibrillar/oligomeric standards for assay calibration. |
| Genetic Mutation Modeling | A53T, A30P, E46K familial PD mutants with verified mutations by sequencing, ideal for seeding and propagation assays. |
| Synuclein Family Selectivity | Homologous β-Synuclein and γ-Synuclein proteins available for counter-screening. |
Live Alpha Synuclein R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for Alpha Synuclein is pivoting from hypothesis validation to clinical differentiation. Following the mixed efficacy signals from first-generation monoclonal antibodies (Prasinezumab, Cinpanemab), the field is stratifying toward conformation-specific targeting—distinguishing between toxic oligomeric species versus aggregated fibrillar deposits. The next wave of R&D emphasizes combination regimens (SNCA immunotherapy plus LRRK2 or GBA modulators), active vaccines inducing endogenous antibody production, small molecule aggregation inhibitors, and emerging modalities like PROTACs and targeted protein degraders for intracellular clearance. Critical unmet needs include blood-brain barrier penetration metrics and patient stratification tools based on synuclein seeding activity. Brain-penetrant delivery mechanisms, such as bispecific antibodies targeting transferrin receptor (TfR1), are under active development to overcome CNS bioavailability challenges.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Roche/Genentech, Biogen, AstraZeneca/Takeda, Prothena | Parkinson's Disease, Multiple System Atrophy (MSA) | Oligomer-selective binding assays using recombinant mutant proteins (A53T, A30P) and conformational standards. |
| Active Vaccine | Affitope, United Neuroscience | Early-stage PD, Prodromal | Immunogenicity assessment requiring high-purity human vs cyno protein comparisons. |
| Small Molecule Aggregation Inhibitor | UCB, Novartis, Neuropore | Parkinson's Disease, Dementia with Lewy Bodies | Aggregation kinetics assays (ThT/fluorescence) requiring endotoxin-free, monomeric protein substrates. |
| ASO/siRNA & Targeted Protein Degraders | Biogen/Ionis, Novartis, Arvinas, Kymera | Genetic Parkinson's, Synucleinopathies | Target engagement validation using SNCA knockdown cell lines, siRNA controls, and cell models for degradation efficiency. |